Brokerages Set uniQure N.V. (NASDAQ:QURE) PT at $65.00

Shares of uniQure N.V. (NASDAQ:QURE) have earned a consensus rating of “Moderate Buy” from the seventeen analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $65.00.

Several analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a research note on Wednesday, June 17th. Barclays decreased their price objective on shares of uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a report on Thursday, July 30th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Leerink Partners raised their target price on uniQure from $36.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, June 18th.

Insider Buying and Selling

In other news, Director Madhavan Balachandran sold 11,685 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the transaction, the director owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. This represents a 21.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of uniQure stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total transaction of $982,995.48. Following the completion of the transaction, the director directly owned 25,996 shares in the company, valued at approximately $1,207,254.24. This represents a 44.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 385,584 shares of company stock worth $16,737,722. Insiders own 4.65% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System boosted its holdings in uniQure by 6,641.2% during the second quarter. California State Teachers Retirement System now owns 2,423,263 shares of the biotechnology company’s stock valued at $111,615,000 after acquiring an additional 2,387,316 shares during the period. Syon Capital LLC bought a new position in shares of uniQure in the second quarter worth about $279,000. Seven Fleet Capital Management LP bought a new position in shares of uniQure in the second quarter worth about $15,254. Diamond Hill Capital Management LLC Investment Advisor bought a new position in shares of uniQure in the second quarter worth about $804,000. Finally, Fulton Bank N.A. acquired a new position in shares of uniQure during the 2nd quarter worth about $220,000. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Down 3.0%

Shares of uniQure stock opened at $44.86 on Tuesday. The firm has a market cap of $3.11 billion, a price-to-earnings ratio of -11.19 and a beta of 0.94. The stock has a 50-day simple moving average of $44.36 and a 200-day simple moving average of $30.24. uniQure has a 52-week low of $8.73 and a 52-week high of $71.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same quarter in the prior year, the company posted ($0.69) EPS. On average, equities research analysts expect that uniQure will post -3.74 earnings per share for the current fiscal year.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure submitted a Biologics License Application (BLA) to the FDA seeking accelerated approval for AMT-130, now known as ifezuntirgene inilparvovec. The company requested Priority Review, which could shorten the FDA review period to six months after the agency’s filing assessment. Reuters article
• Positive Sentiment: The company also filed a U.K. Marketing Authorisation Application, expanding the potential commercial opportunity and adding a second regulatory catalyst. The filings are supported by three-year Phase I/II data indicating that AMT-130 slowed Huntington’s disease progression versus an external natural-history control. The Pharma Letter article
• Positive Sentiment: AMT-130 has received FDA Breakthrough Therapy and RMAT designations, as well as Fast Track status, potentially supporting an expedited review. William Blair resumed coverage with an “Outperform” rating and a $73 fair-value estimate. Benzinga article
• Neutral Sentiment: The FDA’s recent reversal, allowing an accelerated-approval filing despite earlier concerns about the data, materially improved investor sentiment. However, the FDA must still accept the BLA, and approval could require a confirmatory study. uniQure expects to provide four-year clinical data by the end of the third quarter. BioPharma Dive article
• Negative Sentiment: After the large regulatory-driven advance, investors may be locking in gains while awaiting formal filing acceptance and further clinical evidence. Regulatory and trial risks remain significant because the applications rely on relatively small Phase I/II studies and external controls.
• Negative Sentiment: Recent insider-trading data show executives have reported sales and no purchases over the past six months, which may weigh on sentiment following the rally. Quiver Quantitative article

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.